Noninvasive follicular thyroid neoplasm with papillary-like nuclear features
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features
Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a recently recognized entity in the field of thyroid pathology. It represents a distinct category of thyroid nodules that were previously classified as encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC). The reclassification of NIFTP aims to reduce overtreatment of indolent thyroid nodules that do not exhibit aggressive behavior.
Characteristics[edit | edit source]
NIFTP is characterized by the presence of follicular growth pattern with nuclear features resembling papillary thyroid carcinoma, but lacking invasion of the tumor capsule or blood vessels. The nuclear features include nuclear enlargement, overlapping, and grooves, which are typical of papillary thyroid carcinoma. However, the absence of invasion distinguishes NIFTP from EFVPTC.
Diagnosis[edit | edit source]
Diagnosis of NIFTP is based on a combination of histological features, including the absence of invasion and the presence of nuclear features consistent with papillary thyroid carcinoma. Immunohistochemical markers such as thyroid transcription factor-1 (TTF-1) and thyroglobulin can also aid in the diagnosis of NIFTP.
Management[edit | edit source]
The management of NIFTP differs from that of papillary thyroid carcinoma. NIFTP is considered a low-risk lesion with an excellent prognosis, and therefore, conservative management such as observation or lobectomy may be sufficient. Total thyroidectomy and radioactive iodine ablation, which are commonly performed for papillary thyroid carcinoma, are usually not indicated for NIFTP.
Prognosis[edit | edit source]
Patients with NIFTP have an excellent prognosis, with a very low risk of recurrence or metastasis. The reclassification of NIFTP has led to a reduction in unnecessary surgeries and treatments for patients with this indolent thyroid nodule.
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD